Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
BMC Pulm Med ; 24(1): 283, 2024 Jun 17.
Artículo en Inglés | MEDLINE | ID: mdl-38886709

RESUMEN

OBJECTIVE: This comparative analysis aimed to investigate the efficacy of Sivelestat Sodium Hydrate (SSH) combined with Ulinastatin (UTI) in the treatment of sepsis with acute respiratory distress syndrome (ARDS). METHODS: A control group and an observation group were formed with eighty-four cases of patients with sepsis with ARDS, with 42 cases in each group. The control group was intravenously injected with UTI based on conventional treatment, and the observation group was injected with SSH based on the control group. Both groups were treated continuously for 7 days, and the treatment outcomes and efficacy of both groups were observed. The Murray Lung Injury Score (MLIS), Sequential Organ Failure Assessment (SOFA), and Acute Physiology and Chronic Health Evaluation II (APACHE II) were compared. Changes in respiratory function, inflammatory factors, and oxidative stress indicators were assessed. The occurrence of adverse drug reactions was recorded. RESULTS: The total effective rate in the observation group (95.24%) was higher than that in the control group (80.95%) (P < 0.05). The mechanical ventilation time, intensive care unit (ICU) hospitalization time, and duration of antimicrobial medication in the observation group were shorter and multiple organ dysfunction syndrome incidence was lower than those in the control group (P < 0.05). The mortality rate of patients in the observation group (35.71%) was lower than that in the control group (52.38%), but there was no statistically significant difference between the two groups (P > 0.05). MLIS, SOFA, and APACHE II scores in the observation group were lower than the control group (P < 0.05). After treatment, respiratory function, inflammation, and oxidative stress were improved in the observation group (P < 0.05). Adverse reactions were not significantly different between the two groups (P > 0.05). CONCLUSION: The combination of SSH plus UTI improves lung injury and pulmonary ventilation function, and reduces inflammation and oxidative stress in patients with sepsis and ARDS.


Asunto(s)
Quimioterapia Combinada , Glicina , Glicoproteínas , Síndrome de Dificultad Respiratoria , Sepsis , Sulfonamidas , Humanos , Masculino , Sepsis/tratamiento farmacológico , Sepsis/complicaciones , Síndrome de Dificultad Respiratoria/tratamiento farmacológico , Femenino , Persona de Mediana Edad , Glicoproteínas/administración & dosificación , Glicoproteínas/uso terapéutico , Anciano , Glicina/análogos & derivados , Glicina/uso terapéutico , Glicina/administración & dosificación , Sulfonamidas/administración & dosificación , Sulfonamidas/uso terapéutico , Resultado del Tratamiento , Respiración Artificial , APACHE , Adulto , Insuficiencia Multiorgánica/etiología , Insuficiencia Multiorgánica/tratamiento farmacológico , Estrés Oxidativo/efectos de los fármacos , Puntuaciones en la Disfunción de Órganos , Unidades de Cuidados Intensivos , Inhibidores de Tripsina/administración & dosificación , Inhibidores de Tripsina/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA